Dr Robert Motzer (Memorial Sloan Kettering Cancer Centre, New York, USA) presented the results of the CLEAR trial (NCT02811861) [1,2]. This was a multi-centre, randomised, open-label phase 3 trial comparing the efficacy and safety of combination therapy lenvatinib plus either pembrolizumab or everolimus with that of single therapy sunitinib as first-line therapy for patients with advanced RCC. Patients (n=1,069) were randomised 1:1:1 to 1 of 3 treatment arms.
The primary endpoint was PFS as determined by an independent review committee. At the median follow up at 27 months, PFS was significantly longer in the lenvatinib plus pembrolizumab arm compared with the sunitinib arm (median 23.9 months vs 9.2 months; HR 0.39; 95% CI 0.32–0.49; P<0.001). PFS was also significantly longer in the lenvatinib plus everolimus treatment arm than in the sunitinib arm (median 15 months vs 9 months; HR 0.65; 95% CI 0.53–0.80; P<0.001).
Secondary endpoints included OS and ORR. OS was significantly lengthened in the lenvatinib plus pembrolizumab group (HR 0.66; 95% CI 0.49–0.88; P=0.005), but not in the lenvatinib plus everolimus group (HR 1.15; 95% CI 0.88–1.50; P=0.3). ORR was significantly improved in both dual therapy arms: in the lenvatinib plus pembrolizumab arm, ORR was 71% with a complete response rate of 16%; in the lenvatinib plus everolimus arm, ORR was 54% with a complete response rate of 10%; in the sunitinib arm, ORR was 36%, with a complete response rate of 4% (OR 2.15; 95% CI 1.57–2.93).
- Motzer R. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). Abstract 269, ASCO Genitourinary Cancers Symposium, 11–13 February 2021.
- Motzer R, et al. N Engl J Med. 2021 Feb 13. DOI: 10.1056/NEJMoa2035716. Online ahead of print.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Inflammatory markers may guide treatment decisions in metastatic renal cell cancer Next Article
Superior clinical outcomes and QoL with nivolumab plus cabozantinib in RCC »
« Inflammatory markers may guide treatment decisions in metastatic renal cell cancer Next Article
Superior clinical outcomes and QoL with nivolumab plus cabozantinib in RCC »
Table of Contents: ASCO GU 2021
Featured articles
Prostate Cancer
Lu177 as a promising new therapy for metastatic prostate cancer
Role of prostate cancer genomics is evolving
Apalutamide prolongs progression-free survival in prostate cancer
Dose-intensified radiation therapy fails to provide better outcomes in prostate cancer
Intrinsic tumour biology may be predictive of treatment response in prostate cancer
Final TITAN trial results favour use of apalutamide
Penile Cancer
Prognosis of penile cancer associated with HPV status
Renal Cancer
Superior clinical outcomes and QoL with nivolumab plus cabozantinib in RCC
Lenvatinib plus pembrolizumab prolongs survival in renal cell carcinoma
Inflammatory markers may guide treatment decisions in metastatic renal cell cancer
Clinical trial exclusion criteria may lead to lack of evidence in real-world patients: how do the excluded fare?
Axitinib offers hope for improving renal cell cancer surgical outcomes
Cabozantinib as possible new first-line therapy in translocation renal cell carcinoma
Predictors of oral anti-cancer agent utilisation in renal cell carcinoma
Denosumab plus pembrolizumab in advanced clear cell renal cell carcinoma
Testicular Cancer
New prediction model for brain metastasis in germ cell tumours
Reduction in radiation exposure is possible in testicular seminoma surveillance
New therapeutic option for early metastatic seminoma
Urothelial Cancer
Poorer outcomes in bladder cancer predicted by race/ethnicity and gender
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 3 results
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 2 results
New standard of care recommended for patients with upper tract urothelial cancer
Signature DNA alterations in subtypes of bladder cancer
ACE inhibitors associated with superior responses in bladder cancer
Better allocation of research dollars needed
Better prediction of favourable responses to immune checkpoint inhibitors in mUC
Genitourinary Oncology
Researchers call for an overhaul of licensing and funding of anti-cancer drugs
Exploring a new strategy for metastatic germ cell tumours
Related Articles
December 1, 2020
Androgen-deprivation therapy linked to worse fitness, CV mortality
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com